ANIMAL DATA

NEUROCAP®

Effective Nerve-End Barrier

POLYGANICS

TRANSFORMING PATIENT RECOVERY

www.polyganics.com

NEUROCAP®

The Only Dedicated Nerve-end Capping Device

NEUROCAP®
Management of symptomatic peripheral end-neuromas

NEUROCAP®, synthetic and bioresorbable, is the only approved nerve capping device targeted for surgical management of symptomatic end-neuromas. NEUROCAP® is intended to protect a peripheral nerve-end and to reduce the development of a symptomatic neuroma.

Interim animal data support the mechanism of action of NEUROCAP® as an effective nerve-end barrier

In our ongoing animal study, rat sciatic nerve defects were treated by capping the nerve-end with NEUROCAP® compared to a control group that was treated with the cut and bury technique. The effect of NEUROCAP® on the nerve-end and its surrounding tissues will be histologically assessed at 3, 6 and 12 months after implantation on myelin content and axon evaluation, neuroma formation, nerve outgrowth, abnormal healing of the nerve, and any abnormal response in the surrounding nerve tissues.

Preliminary 6-month histological results show NEUROCAP® is safe to use and effective in providing the expected barrier function for the nerve-end, while sprouting and tethering is inhibited.

Schematic representation of the obtained results

NEUROCAP®
Histological evaluation at 3 and 6 months after implantation
(10x total magnification)



NEUROCAP® effectively provides the expected barrier function for the nerve-end, while sprouting is inhibited. The right picture is a graphical illustration of the histological assessment. Dark Blue: outline of NEUROCAP® implant at 3 and 6 months post-op (rat-sciatic nerve); note the extended device degradation at 6 months. Turquoise Blue: collaborated inner part of the NEUROCAP® (no nerve tissue present), marginally observed at 6 months due to further device degradation Orange: Fixating sutures; Magenta Red: outline of nerve-end

CONTROL GROUP

Histological evaluation at 3 and 6 months after implantation
(10x total magnification)



The control group, where the barrier is missing, allows for nerve-end outgrowth. The right picture is a graphical illustration of the histological assessment at 3 and 6 months post-op. *Dark Blue: outline of nerve-end; Magenta Red: outline of newly formed neuroma and fibrotic tissue; Orange: Fixating suture*

Polyganics - Rozenburglaan 15A, 9727 DL Groningen, The Netherlands
T +31 (0)50 588 65 88 - info@polyganics.com - www.polyganics.com

POLYGANICS
TRANSFORMING PATIENT RECOVERY

PG/NC-AD_v2-2017